Characterisation and manipulation of docetaxel resistant prostate cancer cell lines

BACKGROUND: There is no effective treatment strategy for advanced castration-resistant prostate cancer. Although Docetaxel (Taxotere(®)) represents the most active chemotherapeutic agent it only gives a modest survival advantage with most patients eventually progressing because of inherent or acquir...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Neill, Amanda J, Prencipe, Maria, Dowling, Catherine, Fan, Yue, Mulrane, Laoighse, Gallagher, William M, O'Connor, Darran, O'Connor, Robert, Devery, Aoife, Corcoran, Claire, Rani, Sweta, O'Driscoll, Lorraine, Fitzpatrick, John M, Watson, R William G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3203088/
https://www.ncbi.nlm.nih.gov/pubmed/21982118
http://dx.doi.org/10.1186/1476-4598-10-126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3203088/
https://www.ncbi.nlm.nih.gov/pubmed/21982118
http://dx.doi.org/10.1186/1476-4598-10-126

Ejemplares similares